- Capital Cube•2 days ago
Click here to see latest analysisEisai Co., Ltd. reports financial results for the year ended March 31, 2016.We analyze the earnings along side the following peers of Eisai Co., Ltd. – Biogen Inc. (BIIB-US) that have also reported for this period.HighlightsGross margins narrowed from 62.10% to 62.02% compared to the same period last year, operating […] (Read more...) The post Eisai Co., Ltd. :ESALY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 appeared first on CapitalCube.
- Benzinga•9 days ago
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) and Eisai Inc. revealed that the Food and Drug Administration has approved its New Drug Application (NDA) for BELVIQ XR (lorcaserin HCl) CIV extended-release ...
|52wk Range||53.55 - 62.72|
|Day's Range||57.10 - 57.15|
|Avg Vol (3m)||6,047|
As of 9:40 AM EDT. Other OTC Delayed Price. Market open.